FDA approval for new generic product reshapes focus on ANI Pharmaceuticals
ANI Pharmaceuticals (ANIP) received final FDA approval for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension, a generic version of Afinitor Disperz that addresses a U.S. market estimated at about US$123 million in annual sales.
At a share price of US$74.83, ANI Pharmaceuticals has seen its 1 year total shareholder return decline 18.6%, while the 5 year total shareholder return is up 126.96%. Recent 30 day share price gains of 2.75% follow a 90 day share price drop of 9.6%.
Surf 16 high quality undiscovered gems that, like ANI Pharmaceuticals, are pushing fresh product approvals into meaningful revenue pools and could be quietly setting up their next big move.ANI Pharmaceuticals now trades at a steep discount to both analyst price targets and intrinsic value estimates. After the FDA win and a weak 1 year share return, is the caution still warranted or already overdone?
Most Popular Narrative: 34% Undervalued
Against a last close of $74.83, the most followed fair value estimate for ANI Pharmaceuticals sits at $112.71. This frames the latest FDA approval as just one piece of a much larger earnings story built on a 7.1% discount rate.
The company is seeing early-stage expansion in underpenetrated specialties and with prescribers who were previously inexperienced with ACTH therapies (over 50% of new prescribers), indicating long runway for sustained future growth in market share and revenue.
See why 4 investors see ANI Pharmaceuticals as 34% undervalued.
Result: Fair Value of $112.71 (UNDERVALUED)
Still, the ANI Pharmaceuticals story can be knocked off course if payer pushback curbs Cortrophin Gel economics or if high exclusivity exposure attracts faster generic competition.
Find out about the key risks to this ANI Pharmaceuticals narrative.
Next Steps
Mixed message or fresh setup for ANI Pharmaceuticals today. If you want to move fast and rely on your own work, start by weighing the 4 key rewards and 2 important warning signs.
Looking for more ANI Pharmaceuticals investment ideas?
ANI Pharmaceuticals might be on your radar already, but the real edge often comes from lining it up against other opportunities built around clear, data driven filters.
- Spot fresh opportunities that combine quality and attractive pricing by scanning the 32 high quality undervalued stocks before they get crowded.
- Secure more sleep-at-night holdings by focusing on companies with stronger balance sheets using the list of solid balance sheet and fundamentals (25 results).
- Reduce unpleasant surprises by concentrating on steadier opportunities with the 30 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com